NDLI: Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Moon, Joon Ho Sohn, Sang Kyun Kim, Shi Nae Park, Seon Yang Yoon, Sung Soo Kim, In Ho Kim, Hyeoung Joon Kim, Yeo Kyeoung Min, Yoo Hong Cheong, June Won Kim, Jin Seok Jung, Chul Won Kim, Dong Hwan
Spatial Coverage	Republic of Korea
Description	Author Affiliation: Moon JH ( Department of Hematology/Oncology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, 200 Dongduk-Ro, Jung-Gu, Daegu 700-721, Korea.)
Abstract	To achieve successful therapeutic outcomes in chronic myeloid leukemia (CML), continuous and adequate imatinib (Gleevec(®), Glivec(®), Novartis Pharmaceuticals, Basel, Switzerland) dosing is essential. Here, we report a patient counseling program ('Care club', 'Happy club' in Korea) performed to improve patient compliance with imatinib. From January 2006 to December 2008, patients diagnosed with chronic phase CML and taking imatinb were eligible for this retrospective study. A total of 114 patients from 4 centers in Korea were recruited at a 50:50 ratio for Happy club group versus non-Happy club group at each center. During 36-month follow-up, persistency (the number of days of imatinib prescribed versus 1 year) was higher in the Happy club group (98.2 ± 0.03%) than in the non-Happy club group (79.3 ± 0.16%, P = 0.001), whereas dose compliance (miligrams of imatinib that were actually taken versus miligrams that should have been taken) was not different between two groups; 96.5 ± 0.6% and 96.6 ± 0.7% in the Happy club and non-Happy club (P = 0.958). Overall compliance (the product of persistency and dose compliance) improved in the Happy club group (93.0 ± 2.3%) compared with the non-Happy club group (76.2 ± 7.4%, P = 0.001). The patient counseling program was efficient especially in patients who needed high-dose imatinib (>400 mg/day), and overall compliance was 87.8 ± 6.0% in the Happy club group versus 65.5 ± 16.1% in the non-Happy club group (P = 0.017). In conclusion, the patient counseling program was effective in persisting imatinib medication, resulting in the improvement of overall compliance.
File Format	HTM / HTML
ISSN	13570560
Issue Number	2
Volume Number	29
e-ISSN	1559131X
Journal	Medical Oncology
Language	English
Publisher	Springer
Publisher Date	2012-06-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Research Support, Non-u.s. Gov't Cross-sectional Studies Prognosis Comparative Study Humans Middle Aged Male Journal Article Young Adult Patient Education As Topic Pyrimidines Republic Of Korea Counseling Adult Female Retrospective Studies Child Discipline Oncology Piperazines Drug Therapy Antineoplastic Agents Treatment Outcome Leukemia, Myelogenous, Chronic, Bcr-abl Positive Imatinib Mesylate Therapeutic Use Follow-up Studies Adolescent Multicenter Study Statistics & Numerical Data Aged Patient Compliance Benzamides Program Evaluation
Content Type	Text
Resource Type	Article
Subject	Hematology Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.

NICE widens patient group for leukaemia drug.

Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.

Stem cell transplant for chronic myeloid leukemia in the imatinib era.

Multiple skin chloromas: a rare presentation of chronic myelogenous leukaemia in chronic stable phase.

Is b3a2 a better prognostic variant in childhood chronic myeloid leukemia?

Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone.

Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor.

Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.

Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients.

Similar Documents

Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.

NICE widens patient group for leukaemia drug.

Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.

Stem cell transplant for chronic myeloid leukemia in the imatinib era.

Multiple skin chloromas: a rare presentation of chronic myelogenous leukaemia in chronic stable phase.

Is b3a2 a better prognostic variant in childhood chronic myeloid leukemia?

Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone.

Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor.

Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.

Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients.